Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tessera Therapeutics Inc.
Headquarters: Somerville, MA, United States of America
Website: https://www.tesseratherapeu...
Year Founded: 2018
Status: Private
BioCentury | Jan 4, 2025
Emerging Company Profile
Mirai: One-stop shop for genetic medicine developers
With $50M from Flagship, Mirai is optimizing nucleic acid design, delivery and manufacturing for clients
BioCentury | Oct 28, 2024
Product Development
In vivo editing data advances lift hopes for better access
Editas and Tessera report preclinical data for in vivo stem cell editors; Interius doses first patient with an in vivo CAR T
BioCentury | Jun 7, 2024
Regulation
FDA taking broad approach to its new platform technology designation
It will take time for sponsors to develop use cases for the new pathway
BioCentury | Feb 29, 2024
Discovery & Translation
Science spotlight: SOX9 switch for kidney regeneration, improved base editors and more
BioCentury’s roundup of translational innovations
BioCentury | Feb 16, 2024
Product Development
Creating CAR T therapies that don’t cause cancer
Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem
BioCentury | Dec 19, 2023
Discovery & Translation
Next-gen gene editing at ASH
Non-Cas9 enzymes and strategies to improve ex vivo and in vivo engineering of hematopoietic cells are among the innovations
BioCentury | Oct 20, 2023
Discovery & Translation
The emerging base editor toolkit
A deep dive into how academics and biotechs are expanding the therapeutic potential of base editors by iterating on the tech’s three major types
BioCentury | Apr 18, 2023
Management Tracks
Kjems becomes CMO at Ocelot
Plus: New CFO at RS and updates from Tessera and ReCode
BioCentury | Jan 27, 2023
Data Byte
Preclinical biotechs taking larger chunk of venture funding
The percent of venture rounds raised by preclinical biotech has grown over the last five years
BioCentury | Aug 24, 2022
Management Tracks
Bluebird’s Eggimann joins Tessera team
Plus new board appointments at GSK and Alnylam, and updates from Zealand, Pharus and more
Items per page:
1 - 10 of 19